Solid Biosciences (SLDB) Accumulated Depreciation (2017 - 2025)

Solid Biosciences has reported Accumulated Depreciation for 9 years, with the latest figure at $14.2 million in Q4 2025.

• Quarterly Accumulated Depreciation rose 8.94% year-over-year to $14.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.2 million (up 8.94% YoY) and the FY2025 annual result came in at $14.2 million, up 8.94% from the prior year.
• Accumulated Depreciation rose to $14.2 million in Q4 2025 per SLDB's latest filing, from $13.0 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $14.2 million in Q4 2025 and troughed at $9.4 million in Q3 2022.
• A 5-year average of $11.7 million and a median of $11.7 million in 2021 frame the typical range for Accumulated Depreciation.
• The sharpest annual moves came in 2021 and 2022: Accumulated Depreciation jumped 62.23% in 2021, then slipped 13.61% in 2022.
• Over 5 years, Accumulated Depreciation stood at $11.7 million in 2021, then fell by 6.05% to $11.0 million in 2022, then advanced by 16.24% to $12.7 million in 2023, then rose by 2.29% to $13.0 million in 2024, then climbed by 8.94% to $14.2 million in 2025.
• According to Business Quant data, Accumulated Depreciation over the past three periods registered $14.2 million, $13.0 million, and $13.1 million for Q4 2025, Q4 2024, and Q1 2024 respectively.